Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts
02:54am, Monday, 09'th Mar 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Ma
Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights
04:32am, Thursday, 26'th Feb 2026
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported fourth-quarter and full-year 2025 results highlighting continued growth for ARCALYST in recurrent pericarditis, a return to profitability,
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
04:01pm, Wednesday, 25'th Feb 2026
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Hea
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
11:18am, Tuesday, 24'th Feb 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates
10:40am, Tuesday, 24'th Feb 2026
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to a loss of $0.12 per sha
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 24'th Feb 2026
– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 mill
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
04:01pm, Thursday, 19'th Feb 2026
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 a
Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy?
11:01am, Tuesday, 17'th Feb 2026
Kiniksa Pharmaceuticals International, plc (KNSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectat
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
12:40am, Saturday, 24'th Jan 2026
Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
03:30am, Sunday, 18'th Jan 2026
Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:35pm, Monday, 12'th Jan 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kiniksa Pharmaceuticals Provides Corporate Update
07:30am, Monday, 12'th Jan 2026
– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 millio
Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
04:56am, Sunday, 11'th Jan 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) CFO Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 07'th Jan 2026
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Voya Investment Management LLC
04:34am, Monday, 05'th Jan 2026
Voya Investment Management LLC decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 60.8% in the undefined quarter, according to the company in its most rec
